
Øyvind Lie
Looking forward to discussing ACASA-TAVI with this community.
Wouldn’t it be better to diagnose subclinical valve thrombosis first with CT followed bij randomisation of only positive patients to continuing ASA vs DOAC (POPULAR ATLANTIS)
What happened
NOAC monotherapy after TAVI reduced HALT versus aspirin ( (27/167 vs 48/168)) with noninferior safety.
Interventional · Oslo University Hospital
Looking forward to discussing ACASA-TAVI with this community.
ACASA-TAVI co-author
Øyvind Lie
Looking forward to discussing ACASA-TAVI with this community.
Wouldn’t it be better to diagnose subclinical valve thrombosis first with CT followed bij randomisation of only positive patients to continuing ASA vs DOAC (POPULAR ATLANTIS)
“We were able to show substantial reductions in signs of subclinical leaflet thrombosis with NOAC monotherapy, without compromising safety. Results from the ACASA-TAVI trial may establish a new antithrombotic treatment paradigm after TAVI and could be used to inform future guidelines.”
Dr. Øyvind Lie
SAPT remains the standard of care after TAVI
X post ↗Alejandro Lara-García
Younger, lower-bleeding-risk TAVI patients may gain durability from NOAC without added major bleeding
Original post ↗Cath Lab After Hours
Warns that better valve imaging does not equal better patient outcomes and that a 360-patient surrogate-endpoint trial with a mixed DOAC strategy should not overturn current guidance against routine anticoagulation.
Original post ↗Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
The optimal antithrombotic regimen after TAVI is unsettled: aspirin is standard, yet leaflet thrombosis is frequent and its prevention unproven. ACASA-TAVI asked whether NOAC monotherapy protects the valve better without excess bleeding.
Does NOAC monotherapy reduce valve leaflet thrombosis and maintain safety compared to ASA monotherapy in patients aged 65-80 years undergoing TAVI for severe aortic valve stenosis?
| Outcome | NOAC | ASA |
|---|---|---|
| HALT (valve leaflet thrombosis) on 4D CT at 12 months Co-primary efficacy · in-world sources disagree (abstract 16.2% vs 28.6%; structured record 17.2% vs 32.6%); values withheld pending review |
Does NOAC monotherapy reduce valve leaflet thrombosis and maintain safety compared to ASA monotherapy in patients aged 65-80 years undergoing TAVI for severe aortic valve stenosis?
In patients aged 65-80 undergoing TAVI, NOAC monotherapy for 12 months significantly reduced subclinical valve leaflet thrombosis and was noninferior for clinical safety events compared to standard aspirin monotherapy.
Experts see ACASA-TAVI as intriguing but not practice-changing, noting that reduced leaflet thrombosis is a surrogate endpoint and the trial was too small to settle whether NOACs improve hard clinical outcomes after TAVI.
The reaction is cautious: most commentators acknowledge that NOAC monotherapy cut leaflet thrombosis compared with aspirin, but they stress the trial relied on imaging surrogates rather than strokes or mortality. The live question is whether a larger, outcomes-powered trial can justify switching younger, lower-risk TAVI patients away from single antiplatelet therapy.
Multiple clinicians agree the trial does not warrant a change in practice because it was not powered for hard clinical outcomes and leaflet thrombosis on CT remains a surrogate endpoint.
Whether reducing leaflet thrombosis on CT translates into fewer strokes, better valve durability, or improved survival remains unknown. Experts note a dedicated clinical-outcomes trial comparing monotherapy strategies is still needed, and whether younger, lower-bleeding-risk patients represent a subgroup that could benefit from NOACs is unresolved.
NOAC monotherapy reduces TAVI leaflet thrombosis with noninferior safety; extends antithrombotic options beyond aspirin in moderate-risk patients.
Importance: Transcatheter aortic valve implant (TAVI) is increasingly being performed in younger and healthier patients with severe aortic valve stenosis. Antithrombotic therapy after TAVI is a key element of optimizing valve durability and clinical outcomes. Objective: To evaluate the safety and efficacy of a factor Xa inhibitor non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy strategy vs an acetylsalicylic acid (ASA) monotherapy strategy after TAVI. Design, Setting, and Participants: Between December 2021 and June 2025, 360 participants between the ages of 65 and 80 years undergoing TAVI for severe aortic valve stenosis were enrolled in this prospective, randomized, open-label, blinded end point trial conducted at 3 Norwegian centers managing the majority of TAVI procedures nationally. The last patient completed follow-up on May 19, 2026. Intervention: A total of 360 participants were randomly assigned (1:1) to receive 12 months of monotherapy with either NOAC (intervention) or ASA (control). Main Outcomes and Measures: A predefined co-primary end point strategy was chosen to address both efficacy and safety. The primary efficacy end point was TAVI valve leaflet thrombosis defined as the presence of hypoattenuated leaflet thickening (HALT) on blinded core laboratory 4-dimensional cardiac computed tomographic (CT) scan at 12 months. The primary safety end point was a composite of adjudicated Valve Academic Research Consortium 3 (VARC-3) bleeding events, thromboembolic events, and all-cause death at 12 months. Results: Of the 360 participants randomized (mean age, 74.5 years [SD, 3.7]; 134 females [37%]), 336 completed the trial (168 in each group). The primary efficacy end point occurred in 27 participants (16.2%) allocated to the NOAC group and in 48 participants (28.6%) allocated to the ASA group (risk ratio, 0.55; 95% CI, 0.37 to 0.82, P = .004). The primary safety end point occurred in 13 participants (7.5%) in the NOAC group and in 19 participants (10.6%) in the ASA group (risk difference, -3.3%; 95% CI, -9.5% to 2.8%; P for noninferiority <.001). Conclusions and Relevance: A strategy of NOAC monotherapy after TAVI reduced the incidence of HALT and was noninferior for bleeding, thromboembolic events, or death compared with acetylsalicylic acid monotherapy. These findings suggest that anticoagulation therapy can be beneficial after TAVI in selected patients. Trial Registration: ClinicalTrials.gov Identifier: NCT05035277.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Dodgson et al. (2026) conducted an RCT in Severe aortic valve stenosis (n=360). NOAC monotherapy vs. Acetylsalicylic acid (ASA) monotherapy was evaluated on TAVI valve leaflet thrombosis defined as the presence of hypoattenuated leaflet thickening (HALT) on blinded core laboratory 4-dimensional cardiac computed tomographic (CT) scan at 12 months (RR 0.55, 95% CI 0.37 to 0.82, p=.004). NOAC monotherapy reduced TAVI valve leaflet thrombosis at 12 months compared to ASA monotherapy ( (27/167 vs 48/168); risk ratio 0.55.37-0.82;) and was noninferior for safety.
Synapse has enriched 10 related papers. Consider them for comparative context: